Diagnosis, Treatment, and Outcome of Giant-Cell Myocarditis in the Era of Combined Immunosuppression

Circulation: Heart Failure - Tập 6 Số 1 - Trang 15-22 - 2013
Riina Kandolin1, Jukka Lehtonen1, Kaisa Salmenkivi1, Anne Räisänen‐Sokolowski1, Jyri Lommi1, Markku Kupari1
1From the Division of Cardiology, Department of Medicine (R.K., J.L., J.L., M.K.) and the Department of Pathology, HUSLAB (K.S., A.R.-S.), Helsinki University Central Hospital, Helsinki, Finland.

Tóm tắt

Background— Giant-cell myocarditis often escapes diagnosis until autopsy or transplantation and has defied proper treatment trials for its rarity and deadly behavior. Current therapy rests on multiple-drug immunosuppression but its prognostic influence remains poorly known. We set out to analyze (1) our experience in diagnosing giant-cell myocarditis and (2) the outcome of patients on combined immunosuppression. Methods and Results— We reviewed the histories, diagnostic procedures, details of treatment, and outcome of 32 consecutive patients with histologically verified giant-cell myocarditis treated in our hospital since 1991. Twenty-six patients (81%) were diagnosed by endomyocardial or surgical biopsies and 6 at autopsy or post-transplantation. Twenty-eight (88%) patients underwent endomyocardial biopsy. The sensitivity of transvenous endomyocardial biopsy increased from 68% (19/28 patients) to 93% (26/28) after up to 2 repeat procedures. The 26 biopsy-diagnosed patients were treated with combined immunosuppression (2–4 drugs) including cyclosporine in 20 patients. The Kaplan-Meier estimates of transplant-free survival from symptom onset were 69% at 1 year, 58% at 2 years, and 52% at 5 years. Of the transplant-free survivors, 10/17 (59%) experienced sustained ventricular tachyarrhythmias during follow-up and 3 received intracardiac defibrillator shocks for ventricular tachycardia or fibrillation. Conclusions— Repeat endomyocardial biopsies are frequently needed to diagnose giant-cell myocarditis. On contemporary immunosuppession, two thirds of patients reach a partial clinical remission characterized by freedom from severe heart failure and need of transplantation but continuing proneness to ventricular tachyarrhythmias.

Từ khóa


Tài liệu tham khảo

10.1056/NEJM199706263362603

10.1053/sarh.2000.8367

10.1016/S0735-1097(02)02715-8

10.4065/74.12.1221

10.1016/j.amjcard.2008.07.041

10.1136/hrt.2005.079053

10.1111/j.1365-2796.2011.02396.x

10.1016/j.humpath.2005.07.009

10.1161/circep.110.959254

Ren H, Poston RS, Hruban RH, Baumgartner WA, Baughman KL, Hutchins GM. Long survival with giant cell myocarditis. Mod Pathol. 1993;6:402–407.

10.1054/jcaf.2002.32196

10.1016/j.hrthm.2007.06.006